AI for the prediction of early stages of Alzheimer's disease from neuroimaging biomarkers -- A narrative review of a growing field
<|reference_start|>AI for the prediction of early stages of Alzheimer's disease from neuroimaging biomarkers -- A narrative review of a growing field: Objectives: The objectives of this narrative review are to summarize the current state of AI applications in neuroimaging for early Alzheimer's disease (AD) prediction and to highlight the potential of AI techniques in improving early AD diagnosis, prognosis, and management.   Methods: We conducted a narrative review of studies using AI techniques applied to neuroimaging data for early AD prediction. We examined single-modality studies using structural MRI and PET imaging, as well as multi-modality studies integrating multiple neuroimaging techniques and biomarkers. Furthermore, they reviewed longitudinal studies that model AD progression and identify individuals at risk of rapid decline.   Results: Single-modality studies using structural MRI and PET imaging have demonstrated high accuracy in classifying AD and predicting progression from mild cognitive impairment (MCI) to AD. Multi-modality studies, integrating multiple neuroimaging techniques and biomarkers, have shown improved performance and robustness compared to single-modality approaches. Longitudinal studies have highlighted the value of AI in modeling AD progression and identifying individuals at risk of rapid decline. However, challenges remain in data standardization, model interpretability, generalizability, clinical integration, and ethical considerations.   Conclusion: AI techniques applied to neuroimaging data have the potential to improve early AD diagnosis, prognosis, and management. Addressing challenges related to data standardization, model interpretability, generalizability, clinical integration, and ethical considerations is crucial for realizing the full potential of AI in AD research and clinical practice. Collaborative efforts among researchers, clinicians, and regulatory agencies are needed to develop reliable, robust, and ethical AI tools that can benefit AD patients and society.<|reference_end|>
@article{rudroff2024ai,
    title={AI for the prediction of early stages of Alzheimer's disease from
  neuroimaging biomarkers -- A narrative review of a growing field},
    author={Thorsten Rudroff, Oona Rainio and Riku Kl'en},
    journal={arXiv preprint arXiv:2406.17822},
    year={2024},
    doi={10.1007/s10072-024-07649-8},
    archivePrefix={arXiv},
    eprint={2406.17822},
    primaryClass={cs.LG cs.AI}
}